Dr. Thomas A. Abrams, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 239
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 228795
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Beth Israel Deaconess Medical Center Boston, MA
- Newton-Wellesley Hospital Newton, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 239
- Services billed
- 616
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 219 | 97 |
| Established patient office or other outpatient visit, 20-29 minutes | 184 | 118 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 62 | 23 |
| New patient office or other outpatient visit, 45-59 minutes | 50 | 50 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Established patient office or other outpatient visit, 40-54 minutes | 19 | 17 |
| Hospital discharge day management, 30 minutes or less | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Boston, MA | 36 |
| Oxycodone Hcl Other prescribers in Boston, MA | 34 |
| Lonsurf (trifluridine/tipiracil hcl) | 24 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Boston, MA | 22 |
| Lorazepam Other prescribers in Boston, MA | 21 |
| Omeprazole Other prescribers in Boston, MA | 20 |
| Methylphenidate Hcl Other prescribers in Boston, MA | 15 |
| Levothyroxine Sodium Other prescribers in Boston, MA | 13 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 13 |
| Gabapentin Other prescribers in Boston, MA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $3,898 in total to this clinician.
| Histosonics, Inc. | $2,995 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $903 |
| Travel and Lodging | $2,937 |
|---|---|
| Consulting Fee | $820 |
| Food and Beverage | $140 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Histosonics, Inc. May 1, 2025 | Travel and Lodging travel to Plymouth, MN | $2,937 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Consulting Fee | $820 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $45,894 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie Inc. · Active, not recruiting · NCT05822752 - M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.